Canopy Growth Launches Two New Cannabis Formats in Australia

Product Launch Details

Canopy Growth introduced dried flower and cannabis oil products under its Spectrum Therapeutics brand, marking the company's first non-capsule offerings in Australia. The products received approval from the Therapeutic Goods Administration and are now available through Australia's Special Access Scheme and Authorised Prescriber pathways.

Dried flower targets patients seeking inhalation delivery methods. The oil formulation provides an alternative for sublingual or oral administration. Both formats use cannabis cultivated at Canopy's international production facilities.

Market Timing and Competitive Landscape

The launch arrives as Australia's medical cannabis patient count surpassed 280,000 in Q2 2026, up 34% year-over-year according to TGA data. Domestic producers including Cann Group, Little Green Pharma, and Cannatrek currently dominate the flower segment with locally-grown product.

Canopy's entry adds import competition to a market where domestic cultivation has historically held pricing and supply-chain advantages. Wholesale or retail pricing for the new formats hasn't been disclosed.

Regulatory Pathway and Distribution

Both products entered the market through Category B pathways under TGA's Special Access Scheme, allowing prescribers to access unapproved therapeutic goods for individual patients. This route bypasses the full registration process required for general market availability.

Distribution runs through existing pharmaceutical wholesalers that service Australian prescribers. Canopy operates no cultivation or processing facilities in Australia, relying entirely on import logistics from its Canadian and European sites.

Financial Stakes for Canopy

The cleanest read on this launch is market-share defense. Canopy Growth reported international medical revenue of CAD 42 million in its most recent fiscal quarter, with Australia representing an estimated 15-18% of that segment. Flower and oil formats typically command higher per-gram margins than pre-filled capsules or softgels.

The company's international segment has posted consecutive quarters of declining revenue as European markets matured and competition intensified. Australia remains one of the few medical markets with double-digit patient growth, which explains the timing.

Domestic Cultivation Dynamics

Australia licensed 87 domestic cultivation sites as of August 2026, up from 61 in 2025, creating oversupply conditions that have pressured wholesale prices 22% year-over-year. Imported product faces a structural cost disadvantage: freight, compliance testing, and currency conversion add an estimated AUD 2-3 per gram to landed cost.

Canopy will need to compete on strain selection, consistency, or brand equity rather than price. Which cultivars it's launching in flower format remains undisclosed.

What to Watch

Prescriber uptake data will clarify whether Canopy's brand recognition translates to market share in flower and oil categories dominated by local producers. Next signal: Q3 international revenue figures, expected in November, which will show whether the format expansion arrests the segment's decline. For full background on Australia's medical cannabis market dynamics, see the CannIntel topic hub on Australia Medical Cannabis Market.